AU2019277920A1 - Compositions and methods of using same for treating amyotrophic lateral sclerosis (ALS) - Google Patents

Compositions and methods of using same for treating amyotrophic lateral sclerosis (ALS) Download PDF

Info

Publication number
AU2019277920A1
AU2019277920A1 AU2019277920A AU2019277920A AU2019277920A1 AU 2019277920 A1 AU2019277920 A1 AU 2019277920A1 AU 2019277920 A AU2019277920 A AU 2019277920A AU 2019277920 A AU2019277920 A AU 2019277920A AU 2019277920 A1 AU2019277920 A1 AU 2019277920A1
Authority
AU
Australia
Prior art keywords
peptide
als
subject
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019277920A
Other languages
English (en)
Inventor
Eran Ovadia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunity Pharma Ltd
Original Assignee
Immunity Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunity Pharma Ltd filed Critical Immunity Pharma Ltd
Publication of AU2019277920A1 publication Critical patent/AU2019277920A1/en
Priority to AU2025201060A priority Critical patent/AU2025201060A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2019277920A 2018-05-31 2019-05-30 Compositions and methods of using same for treating amyotrophic lateral sclerosis (ALS) Abandoned AU2019277920A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201060A AU2025201060A1 (en) 2018-05-31 2025-02-14 Compositions and methods of using same for treating amyotrophic lateral sclerosis (ALS)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678316P 2018-05-31 2018-05-31
US62/678,316 2018-05-31
PCT/IL2019/050619 WO2019229757A1 (en) 2018-05-31 2019-05-30 Compositions and methods of using same for treating amyotrophic lateral sclerosis (als)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201060A Division AU2025201060A1 (en) 2018-05-31 2025-02-14 Compositions and methods of using same for treating amyotrophic lateral sclerosis (ALS)

Publications (1)

Publication Number Publication Date
AU2019277920A1 true AU2019277920A1 (en) 2021-01-07

Family

ID=68697171

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019277920A Abandoned AU2019277920A1 (en) 2018-05-31 2019-05-30 Compositions and methods of using same for treating amyotrophic lateral sclerosis (ALS)
AU2025201060A Pending AU2025201060A1 (en) 2018-05-31 2025-02-14 Compositions and methods of using same for treating amyotrophic lateral sclerosis (ALS)

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201060A Pending AU2025201060A1 (en) 2018-05-31 2025-02-14 Compositions and methods of using same for treating amyotrophic lateral sclerosis (ALS)

Country Status (7)

Country Link
US (1) US20210100869A1 (https=)
EP (1) EP3785279A4 (https=)
JP (1) JP7350019B2 (https=)
AU (2) AU2019277920A1 (https=)
IL (1) IL279108B2 (https=)
MX (1) MX2020012532A (https=)
WO (1) WO2019229757A1 (https=)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
SK151599A3 (en) 1997-05-14 2000-09-12 Rhone Poulenc Rorer Pharma Peptide parathyroid hormone analogs
AU8726201A (en) * 2000-03-31 2001-10-08 Smithkline Beecham Plc Use of CRF receptor agonists for the treatment of prophylaxis of diseases, for example neurodegenerative diseases
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
HUE024953T2 (en) * 2004-08-23 2016-02-29 Yeda Res & Dev Peptide inhibitors to mediate stress responses
AU2005298383A1 (en) * 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
ES2407454T3 (es) * 2006-11-10 2013-06-12 Genervon Biopharmaceuticals Llc Métodos de tratamiento de trastornos neuronales utilizando péptidos MNTF y análogos de los mismos
CA2689476C (en) * 2007-06-07 2014-08-05 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
EP2715350B1 (en) 2011-05-23 2017-09-27 Yeda Research and Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2016040877A1 (en) * 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
CA3193811A1 (en) * 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)

Also Published As

Publication number Publication date
JP2021524858A (ja) 2021-09-16
US20210100869A1 (en) 2021-04-08
AU2025201060A1 (en) 2025-03-20
IL279108B1 (en) 2024-06-01
CA3099846A1 (en) 2019-12-05
EP3785279A4 (en) 2022-07-27
IL279108B2 (en) 2024-10-01
JP7350019B2 (ja) 2023-09-25
WO2019229757A1 (en) 2019-12-05
EP3785279A1 (en) 2021-03-03
MX2020012532A (es) 2021-04-28
IL279108A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
Adams Jr et al. A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia.
TW202128183A (zh) 用於治療多種病症之方法及組成物
Cocohoba et al. Valganciclovir: an advance in cytomegalovirus therapeutics
CN103167877A (zh) 包含谷胱甘肽还原酶和氧化型谷胱甘肽的组合物，以及其治疗用途
EP3937944B1 (en) Toll-like receptor agonists for use in the treatment of hepatitis b
US20100061935A1 (en) Methods of using sustained release aminopyridine compositions
EP4378949A1 (en) Neuroprotective polypeptide compound and application thereof
CA3099846C (en) Compositions and methods of using same for treating amyotrophic lateral sclerosis (als)
US20210100869A1 (en) Compositions and methods of using same for treating amyotrophic lateral sclerosis (als)
RU2851806C1 (ru) Композиции и способы их применения для лечения амиотрофического латерального склероза (als)
RU2804764C2 (ru) Композиции и способы их применения для лечения амиотрофического латерального склероза (als)
AU2022240726A1 (en) Copper histidinate compositions and uses thereof
AU2021290173A1 (en) Rabeximod in the treatment of rheumatoid arthritis
US20240374691A1 (en) Glp-1r agonists for use in a treatment of neurologial impairment associated with viral infection
US20130109615A1 (en) Methods for inhibiting necrosis
Barshop et al. Kearns–Sayre syndrome presenting as 2-oxoadipic aciduria
Stancioiu et al. Post-stroke recovery of motor function with a new combination of medicines-A pilot study
RU2235550C2 (ru) Лекарственное средство бионормализующего действия и способ его получения
US20230190697A1 (en) Methods for treating viral infections with nafamostat
JP2002522507A (ja) 疾患状態の処置
AU2005332686B2 (en) Methods for providing palliative care with AVR118
US20230364156A1 (en) Treating of neurological disorders using extracellular vesicles released by human induced pluripotent stem cell derived neural stem cells
RU2278687C1 (ru) Способ лечения ремиттирующего рассеянного склероза
WO2022100737A1 (zh) 一种格列本脲的经鼻给药的药物组合物及其制备方法
HK40081935A (en) Treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted